A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
In collaboration with the National Institutes of Health (NIH), Banner Alzheimer’s Institute (BAI), University of Antioquia in Colombia and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announce the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. This groundbreaking study—the first to investigate whether an anti-amyloid treatment can stave off the disease—will span two countries and help launch a new era of prevention research in the urgent fight against Alzheimer’s.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56128-banner-alzheimer-s-institute-genentech-nih-prevention-trial-genetics
The National Bone Health Alliance (NBHA), a public-private partnership with 42 member organizations, is urging a simple solution to a big problem: if it’s 50+ fracture, request a test. This is the call-to-action for the NBHA’s new public and healthcare professional education campaign – 2Million2Many (www.2Million2Many.org).
The campaign reflects the two million bone breaks that occur in the U.S. each year that are caused by osteoporosis and urges the public and healthcare professionals alike to take action and request a test for osteoporosis when someone age 50 or older breaks a bone. Despite the fact that 50 percent of osteoporosis-related repeat fractures can be prevented with existing treatments, only two in 10 initial bone breaks get a follow-up test or treatment for osteoporosis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56192-national-bone-health-alliance-nbha-prevent-osteoporosis-2million2many
Having a confident smile is important at any age, even more so when you grow up in the spotlight and need to be close-up ready at any moment. In search of a picture perfect smile, many young stars are turning to modern new options that straighten their teeth.
Today, treatment can take place with Invisalign - a clear and removable option that allows teeth-straightening to go nearly unnoticed because the braces are virtually invisible. A series of clear aligners move teeth gradually over time. Gone are the days when straightening teeth means you have to wear metal braces and deal with all the challenges associated with them.
To view Multimedia News Release, go to http://www.multivu.com/players/English/53352-invisalign-secret-to-hollywood-smiles/
Go
to http://www.youtube.com/watch?v=iEaPlJkCUfA Aurawave Pain Reliever As
Seen On TV treatment for your back pain. If you are sick and tired with
your body aches and pains. If you think the only solution for pain
reliever is to take over-the-counter pain relievers. Well, think again
with Aurawave Pain Reliever As Seen On TV, pain is gone.
Today the Confederation of Meningitis Organisations (CoMO) is urging people all over the world to “Join Hands Against Meningitis” in an effort to reduce the global impact of the disease. The call-to-action encourages individuals, families and communities to learn the signs and symptoms of meningitis, the importance of urgent treatment of the disease, and that prevention is available through vaccination against some forms of meningitis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55808-world-meningitis-day-join-the-fight-to-stop-meningitis
With the official arrival of spring and the official start to flea and tick season, PetArmor® has teamed up with the ASPCA® (The American Society for the Prevention of Cruelty to Animals®) and shelter animal advocate and PetArmor® spokesperson Amy Smart to launch the PetArmor® Protection Promise. The national campaign elevates the ongoing commitment PetArmor® and the ASPCAshare to protect pets in need. PetArmor® is the No. 1 selling fipronil generic flea and tick treatment. PetArmor® has the same No. 1 veterinarian recommended active ingredient and offers the same flea and tick protection as Frontline® Top Spot® at about half the cost. The PetArmor® Protection Promise offers pet lovers and dog and cat owners an opportunity to help pets in need, especially those in shelters across the country.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55464-amy-smart-petarmor-aspca-launch-protection-promise-healthcare-for-all-pets
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
Approximately 80 million American men and women experience some form of hair loss. Premature balding or thinning hair can often result in a decrease of self esteem. Freedom Laser Therapy of Los Angeles is dedicated to change all that by bringing their iRestore Hair Rejuvenation System to the mass market.
This proven, safe Laser Hair Restoration Technology, otherwise known as phototherapy, is a scientific process providing stimulation to cells in your hair. The 25-year old advanced low-level laser treatment stimulates the scalp, allowing miniaturized and dormant hair follicles to rejuvenate.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54394-freedom-laser-therapy-laser-hair-treatment-regrowth-restoration
http://www.ftrintl.com/ FTR International Inc. is a an award-winning and highly innovative Union general contracting, engineering, and construction management firm that has successively proven its exceptional ethic in the successful delivery of over 100 multi-million dollar projects since our initiation in 1984. With offices in Irvine and Los Angeles, California, FTR prides itself with a diverse public works and private project portfolio, totaling billions of dollars' worth of construction costs in General Contracting, Design/Build and Construction Management delivery. Our diverse project portfolio includes state-of-the-art science laboratories, health centers, educational institutions, aviation terminals, art and theater facilities, ultra-modern mass transit stations, port security services, complex water reclamations, environmental sewage treatment facilities, and electrical power distribution centers and our industry reach extends to more than sixty public agencies.
